(4) Subsequent events
On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of Springworks Therapeutics, Inc., USA. At the time of the preparation of the Consolidated Financial Statements, there existed no certainty that a merger agreement would be signed.
Subsequent to the balance sheet date, no other events of special importance occurred that are expected to have a material impact on the net assets, financial position, or results of operations.